Adtalem Global Education (NYSE:CVSA) Director Michael Malafronte Acquires 8,890 Shares

Key Points

• Insider purchase: Director Michael Malafronte bought 8,890 shares at an average price of $100.94 (≈$897,357), increasing his stake 53.86% to 25,395 shares (≈$2.56M), disclosed in an SEC filing.
• Company fundamentals: CVSA traded at $100.90 (down 0.2%) with a $3.48B market cap, a P/E of 14.82, and recent quarterly results of $2.43 EPS on $503.39M revenue, with a 20.24% ROE.
• Analyst sentiment: MarketBeat shows a consensus "Buy" and an average target of $170, with recent upgrades including Zacks to "Strong Buy" and Barrington Research reiterating an "Outperform" rating with a $170 target.

Adtalem Global Education Inc. (NYSE:CVSA - Get Free Report) Director Michael Malafronte purchased 8,890 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The shares were bought at an average cost of $100.94 per share, with a total value of $897,356.60. Following the transaction, the director directly owned 25,395 shares of the company's stock, valued at $2,563,371.30. The trade was a 53.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Adtalem Global Education Stock Down 0.2%

Shares of NYSE CVSA traded down $0.20 during trading on Thursday, hitting $100.90. 43,310 shares of the company traded hands, compared to its average volume of 434,531. The stock has a market capitalization of $3.48 billion, a PE ratio of 14.82, a P/E/G ratio of 0.85 and a beta of 0.72. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. Adtalem Global Education Inc. has a 1 year low of $86.97 and a 1 year high of $156.26.

Adtalem Global Education (NYSE:CVSA - Get Free Report) last issued its earnings results on Wednesday, January 28th. The company reported $2.43 earnings per share for the quarter. Adtalem Global Education had a return on equity of 20.24% and a net margin of 13.41%.The business had revenue of $503.39 million for the quarter.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CVSA shares. Zacks Research raised shares of Adtalem Global Education from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 24th. Barrington Research reissued an "outperform" rating and issued a $170.00 target price on shares of Adtalem Global Education in a research note on Monday, March 2nd. Finally, Weiss Ratings began coverage on shares of Adtalem Global Education in a report on Wednesday, February 25th. They set a "hold (c+)" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Adtalem Global Education presently has a consensus rating of "Buy" and an average target price of $170.00.

About Adtalem Global Education

Adtalem Global Education NYSE: CVSA is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.